Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22714305 | 1.00 | GRIN2B (0.46) | GRIN2BGRIN1LMNACLK4MEN1 | |
| SCHEMBL24673902 | 0.90 | LMNA (0.48) | GRIN2BGRIN1LMNACLK4MEN1 | |
| SCHEMBL29564796 | 0.90 | LMNA (0.48) | GRIN2BGRIN1LMNACLK4MEN1 | |
| SCHEMBL22714970 | 0.82 | GRIN1 (0.38) | GRIN2BGRIN1LMNATP53HTT | |
| SCHEMBL22726067 | 0.81 | HTT (0.38) | GRIN2BGRIN1LMNACLK4MEN1 | |
| SCHEMBL22714182 | 0.78 | HTT (0.40) | LMNACLK4MEN1KMT2ATP53 | |
| SCHEMBL24673938 | 0.78 | LMNA (0.48) | GRIN2BGRIN1LMNACLK4MEN1 | |
| SCHEMBL22714800 | 0.77 | GRIN2B (0.38) | GRIN2BGRIN1LMNACLK4MEN1 | |
| SCHEMBL22714614 | 0.77 | EGFR (0.45) | GRIN2BGRIN1LMNACLK4MEN1 | |
| SCHEMBL29563939 | 0.77 | EGFR (0.45) | GRIN2BGRIN1LMNACLK4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976609-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | claimed |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-04-21 | — | — | US | disclosed |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-06 | — | — | US | disclosed |
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235060-A1 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | GRIN2B 2554/4885GRIN1 2214/4885LMNA 3597/4885 |
| US-12606562-B2 | Pyridopyrimidines derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX2 | GRIN2B 2575/4885GRIN1 1892/4885LMNA 2712/4885 |
| US-20230212169-A9 | PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | GRIN2B 2554/4885GRIN1 2214/4885LMNA 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.